Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 8
2021 33
2022 22
2023 20
2024 16
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Target-driven functionalized DNA hydrogel capillary sensor for SARS-CoV-2 dual-mode detection.
Jiao JB, Kang Q, Cui SX, Cao JL, Lin T, Ma CJ, Xiao ZH, Du T, Wang N, Du XJ, Wang S. Jiao JB, et al. Talanta. 2024 Dec 4;285:127342. doi: 10.1016/j.talanta.2024.127342. Online ahead of print. Talanta. 2024. PMID: 39644672
Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused secondary pandemic, which still poses a serious threat to physical health and economic development. Herein, the target-driven functionalized DNA hydrogel cap …
Coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused secondary pandemi …
Au@Pt@Pd nanozymes based lateral flow immunoassay for quantitative detection of SARS-CoV-2 nucleocapsid protein in nasal swab samples.
Li C, Lu J, Xiang C, Zhang E, Tian X, Zhang L, Li T, Li C. Li C, et al. Mikrochim Acta. 2024 Nov 7;191(12):730. doi: 10.1007/s00604-024-06819-x. Mikrochim Acta. 2024. PMID: 39508966
Three-metal-core-shell nanoparticles (Au@Pt@PdNPs) providing excellent peroxidase-like activity were applied in lateral flow immunoassay (LFIA), designated as Au@Pt@Pd-LFIA, for detecting the nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus 2 (SARS …
Three-metal-core-shell nanoparticles (Au@Pt@PdNPs) providing excellent peroxidase-like activity were applied in lateral flow immunoassay (LF …
Au@Pt nanoparticles-based signal-enhanced lateral flow immunoassay for ultrasensitive naked-eye detection of SARS-CoV-2.
Li X, Li H, Zhu JY, Yu D, Abulaiti T, Zeng J, Wen CY. Li X, et al. Mikrochim Acta. 2024 Oct 9;191(11):657. doi: 10.1007/s00604-024-06697-3. Mikrochim Acta. 2024. PMID: 39382589
With SARS-CoV-2 N protein as a model target, a signal-enhanced LFIA based on Au@Pt nanoparticles (NPs) as labels is proposed. ...
With SARS-CoV-2 N protein as a model target, a signal-enhanced LFIA based on Au@Pt nanoparticles (NPs) as labels is pro …
Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.
Bahce I, Dickhoff C, Schneiders FL, Veltman J, Heineman DJ, Hashemi SMS, Vrijmoet A, Houda I, Ulas EB, Bakker J, van de Ven P, Bouwhuis N, Meijboom LJ, Oprea-Lager DE, van Maldegem F, Fransen MF, de Gruijl TD, Radonic T, Senan S. Bahce I, et al. J Immunother Cancer. 2024 Sep 30;12(9):e009799. doi: 10.1136/jitc-2024-009799. J Immunother Cancer. 2024. PMID: 39349061 Free PMC article. Clinical Trial.
Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT, IPI 1 mg/kg intravenous and NIVO 360 mg intravenous on day-1, followed by chemotherapy plus NIVO 360 mg 3 weeks later. ...RESULTS: In a to …
Primary study endpoints were safety, major pathological response (MPR) and pCR. Treatment encompassed platinum-doublet concurrent CRT …
Rapid SARS-CoV-2 sensing through oxygen reduction reaction catalysed by Au@Pt/Au core@shell nanoparticles.
Martínez-Periñán E, Palomares-Albarrán M, Toyos-Rodríguez C, Mateo-Martí E, Pariente F, Escosura-Muñiz A, Gutiérrez-Sánchez C, Revenga-Parra M, Lorenzo E. Martínez-Periñán E, et al. Talanta. 2024 Dec 1;280:126708. doi: 10.1016/j.talanta.2024.126708. Epub 2024 Aug 13. Talanta. 2024. PMID: 39151318 Free article.
The development of rapid, accurate, sensitive, and low-cost diagnostic methods for COVID-19 detection in real-time is the unique way to control infection sources and monitor illness progression. ...Based on this strategy, target sequences of the SARS-CoV …
The development of rapid, accurate, sensitive, and low-cost diagnostic methods for COVID-19 detection in real-time is the uniq …
Simple and Ultrasensitive Nanozyme-Linked Immunosorbent Assay for SARS-CoV-2 Detection on a Syringe-Driven Filtration Device.
Wang Z, Chen H, Cheng X, Wang Y, Wei H, Rong Z, Wang S. Wang Z, et al. ACS Appl Mater Interfaces. 2024 Aug 28;16(34):44485-44492. doi: 10.1021/acsami.4c08787. Epub 2024 Aug 16. ACS Appl Mater Interfaces. 2024. PMID: 39150764
This detection method could realize the quantitative detection of SARS-CoV-2 NP within 80 min for point-of-care needs. The limit of detection for the SARS-CoV-2 antigen was 0.01 ng/mL in buffer. The coefficients of variation of the assay …
This detection method could realize the quantitative detection of SARS-CoV-2 NP within 80 min for point-of-care needs. …
Lab-in-a-Vial Rapid Test for Internet of Things-Embedded Point-of-Healthcare Protein Biomarker Detection in Bodily Fluids.
Li NS, Hsu YP, Pang HH, Wang SF, Pang ST, Lin CY, Tsai RY, Huang CY, Wei KC, Yang HW. Li NS, et al. Small. 2024 Dec;20(50):e2400878. doi: 10.1002/smll.202400878. Epub 2024 Aug 6. Small. 2024. PMID: 39105375
This study introduces a Lab-in-a-Vial (LV) rapid diagnostic platform, featuring hydrangea-like platinum nanozymes (PtNH), for rapid, accurate detection and quantification of protein biomarkers on-site within 15 min. ...The platform's effectiveness and adaptability are conf …
This study introduces a Lab-in-a-Vial (LV) rapid diagnostic platform, featuring hydrangea-like platinum nanozymes (PtNH), for rapid, …
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.
Bellmunt J, Maroto P, Bonfill T, Vazquez F, Perez-Gracia JL, Juanpere N, Hernandez-Prat A, Hernandez-Llodra S, Rovira A, Juan O, Rodriguez-Vida A. Bellmunt J, et al. Clin Genitourin Cancer. 2024 Oct;22(5):102123. doi: 10.1016/j.clgc.2024.102123. Epub 2024 May 23. Clin Genitourin Cancer. 2024. PMID: 38905731 Clinical Trial.
PATIENTS AND METHODS: This was an open-label, investigator-initiated phase II study evaluating safety and efficacy of sapanisertib plus paclitaxel in patients with mUC who had progressed to prior platinum therapy, and the correlation with NFE2L2 mutations in responders. Pr …
PATIENTS AND METHODS: This was an open-label, investigator-initiated phase II study evaluating safety and efficacy of sapanisertib plus pacl …
Strengthening education and training programmes for medical physics in Asia and the Pacific: the IAEA non-agreement technical cooperation (TC) regional RAS6088 project.
Jamal N, Krisanachinda A, Tsapaki V, Islam MR, Pawiro S, Al Omari M, Yeong CH, Myint TT, Kakakhel MB, Kharita MH, Lee CLJ, Ismail A, Nguyen TB, Knoll P, Ciraj-Bjelac O, Malek M. Jamal N, et al. Phys Eng Sci Med. 2024 Sep;47(3):1167-1176. doi: 10.1007/s13246-024-01437-6. Epub 2024 May 28. Phys Eng Sci Med. 2024. PMID: 38807011
In conclusion, the RAS6088 project was found to have achieved its planned outcomes despite challenges faced due to the COVID-19 pandemic. It is proposed that a follow up project be implemented to increase the number of Member States who are better prepared to improv …
In conclusion, the RAS6088 project was found to have achieved its planned outcomes despite challenges faced due to the COVID-19 …
83 results